Single-dose pharmacokinetics of intravenous ampicillin plus sulbactam in healthy elderly and young adult subjects
- PMID: 2613605
- DOI: 10.1093/jac/24.4.573
Single-dose pharmacokinetics of intravenous ampicillin plus sulbactam in healthy elderly and young adult subjects
Abstract
The pharmacokinetics of intravenous ampicillin and sulbactam, a beta-lactamase inhibitor, were evaluated in two different age groups. Twelve healthy elderly subjects (age 65-93 years) and 12 healthy young adult subjects (age 20-35 years) received both a dose of ampicillin 1 g plus sulbactam 0.5 g and a higher dose of ampicillin 2 g plus sulbactam 1 g after a one-week period between doses. A reverse-phase high-pressure liquid chromatography method was used for the quantitation of ampicillin and sulbactam in serum and urine. The pharmacokinetic parameters for both ampicillin and sulbactam were calculated by computer-based two-compartment nonlinear model. After a 30-min infusion, serum concentrations of both drugs declined in a biexponential manner for both doses. Elderly subjects demonstrated significantly lower total clearances (Clt) than young adult subjects of ampicillin 1 g (220.0 +/- 104.2 vs 360.0 +/- 95.8 ml/min/1.73 m2), ampicillin 2 g (72.6 +/- 36.6 vs 306.8 +/- 109.77 ml/min/1.73 m2), sulbactam 0.5 g (122.3 +/- 47.8 vs 263.9 +/- 93.7 ml/min/1.73 m2), and sulbactam 1 g (171.2 +/- 85.8 vs 391.7 +/- 70.8 ml/min/1.73 m2), respectively. Significance was defined as P less than 0.05. Renal clearance was also significantly reduced in the elderly subjects. Area under the curve was found to be significantly increased in the elderly subjects compared to the young subjects for both ampicillin and sulbactam as were the beta elimination half-lives. No significant difference in the apparent volume of distribution, when adjusted for body weight, was found for either sulbactam (P greater than 0.95) or ampicillin (P greater than 0.95) between the two groups. Linear regression analysis revealed that age was significantly correlated with the Clt of ampicillin 1 g (r = 0.85, P less than 0.001), ampicillin 2 g (r = 0.90, P less than 0.001), sulbactam 0.5 g (r = 0.80, P less than 0.001), and sulbactam 1 g (r = 0.93, P less than 0.001). A multivariate analysis showed a slight improvement in correlation when creatinine clearance was added to age and compared with Clt. Urinary recovery of both ampicillin and sulbactam was approximately 60% after 14 h.
Similar articles
-
Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis.Antimicrob Agents Chemother. 1989 Sep;33(9):1470-6. doi: 10.1128/AAC.33.9.1470. Antimicrob Agents Chemother. 1989. PMID: 2817847 Free PMC article.
-
Pharmacokinetics of sulbactam/ampicillin in humans after intravenous and intramuscular injection.Chemotherapy. 1990;36(3):185-92. doi: 10.1159/000238765. Chemotherapy. 1990. PMID: 2338029 Clinical Trial.
-
Single-dose pharmacokinetics of ampicillin/sulbactam (2:1) combination after intravenous administration to sheep and goats.Res Vet Sci. 1996 Sep;61(2):143-6. doi: 10.1016/s0034-5288(96)90089-2. Res Vet Sci. 1996. PMID: 8880984
-
Sulbactam/ampicillin, a new beta-lactamase inhibitor/beta-lactam antibiotic combination.Drug Intell Clin Pharm. 1988 Jul-Aug;22(7-8):534-41. doi: 10.1177/106002808802200702. Drug Intell Clin Pharm. 1988. PMID: 3046887 Review.
-
Pharmacokinetics of sulbactam/ampicillin in humans: a review.Rev Infect Dis. 1986 Nov-Dec;8 Suppl 5:S503-11. doi: 10.1093/clinids/8.supplement_5.503. Rev Infect Dis. 1986. PMID: 3025997 Review.
Cited by
-
Population Pharmacokinetics and Dosing Simulations of Ampicillin and Sulbactam in Hospitalised Adult Patients.Clin Pharmacokinet. 2023 Apr;62(4):573-586. doi: 10.1007/s40262-023-01219-5. Epub 2023 Feb 28. Clin Pharmacokinet. 2023. PMID: 36853585 Free PMC article.
-
Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly.Clin Pharmacokinet. 2020 Mar;59(3):383-401. doi: 10.1007/s40262-019-00822-9. Clin Pharmacokinet. 2020. PMID: 31583609
-
Lower Body Mass Index is a Risk Factor for In-Hospital Mortality of Elderly Japanese Patients Treated with Ampicillin/sulbactam.Int J Med Sci. 2016 Sep 19;13(10):749-753. doi: 10.7150/ijms.16090. eCollection 2016. Int J Med Sci. 2016. PMID: 27766023 Free PMC article.
-
Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa.Antimicrob Agents Chemother. 1997 Feb;41(2):435-9. doi: 10.1128/AAC.41.2.435. Antimicrob Agents Chemother. 1997. PMID: 9021203 Free PMC article. Clinical Trial.
-
Ampicillin/sulbactam in elderly patients with community-acquired pneumonia.Infection. 2014 Feb;42(1):79-87. doi: 10.1007/s15010-013-0518-8. Epub 2013 Aug 1. Infection. 2014. PMID: 23904004
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical